166 related articles for article (PubMed ID: 26478018)
1. Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug.
Park CG; Kim YK; Kim MJ; Park M; Kim MH; Lee SH; Choi SY; Lee WS; Chung YJ; Jung YE; Park KH; Choy YB
J Control Release; 2015 Dec; 220(Pt A):180-188. PubMed ID: 26478018
[TBL] [Abstract][Full Text] [Related]
2. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
[TBL] [Abstract][Full Text] [Related]
3. Nanostructured mucoadhesive microparticles for enhanced preocular retention.
Park CG; Kim MJ; Park M; Choi SY; Lee SH; Lee JE; Shin GS; Park KH; Choy YB
Acta Biomater; 2014 Jan; 10(1):77-86. PubMed ID: 23978409
[TBL] [Abstract][Full Text] [Related]
4. Metal-organic frameworks, NH
Kim SN; Park CG; Huh BK; Lee SH; Min CH; Lee YY; Kim YK; Park KH; Choy YB
Acta Biomater; 2018 Oct; 79():344-353. PubMed ID: 30134206
[TBL] [Abstract][Full Text] [Related]
5. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles.
Park CG; Kim YK; Kim SN; Lee SH; Huh BK; Park MA; Won H; Park KH; Choy YB
Int J Pharm; 2017 Apr; 522(1-2):66-73. PubMed ID: 28216468
[TBL] [Abstract][Full Text] [Related]
6. Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate.
Singh KH; Shinde UA
Curr Drug Deliv; 2010 Jul; 7(3):244-51. PubMed ID: 20497099
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Aburahma MH; Mahmoud AA
AAPS PharmSciTech; 2011 Dec; 12(4):1335-47. PubMed ID: 21979886
[TBL] [Abstract][Full Text] [Related]
8. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Suzuki G; Kunikane E; Shigemi W; Shinno K; Kozai S; Kurata M; Kawamura A
Curr Eye Res; 2021 Mar; 46(3):380-386. PubMed ID: 32706598
[TBL] [Abstract][Full Text] [Related]
9. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
10. Thermosensitive hexanoyl glycol chitosan-based ocular delivery system for glaucoma therapy.
Cho IS; Park CG; Huh BK; Cho MO; Khatun Z; Li Z; Kang SW; Choy YB; Huh KM
Acta Biomater; 2016 Jul; 39():124-132. PubMed ID: 27163401
[TBL] [Abstract][Full Text] [Related]
11. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Bhagav P; Upadhyay H; Chandran S
AAPS PharmSciTech; 2011 Dec; 12(4):1087-101. PubMed ID: 21879393
[TBL] [Abstract][Full Text] [Related]
12. Mucoadhesive microparticles in a rapidly dissolving tablet for sustained drug delivery to the eye.
Choy YB; Patel SR; Park JH; McCarey BE; Edelhauser HF; Prausnitz MR
Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2627-33. PubMed ID: 21245405
[TBL] [Abstract][Full Text] [Related]
13. Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma.
Sharma PK; Chauhan MK
Curr Eye Res; 2021 Nov; 46(11):1703-1716. PubMed ID: 33844617
[No Abstract] [Full Text] [Related]
14. Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients.
Barwal I; Kumar R; Dada T; Yadav SC
Microsc Microanal; 2019 Dec; 25(6):1352-1366. PubMed ID: 31018876
[TBL] [Abstract][Full Text] [Related]
15. Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time.
Choy YB; Park JH; McCarey BE; Edelhauser HF; Prausnitz MR
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4808-15. PubMed ID: 18689699
[TBL] [Abstract][Full Text] [Related]
16. Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles.
Schnichels S; Hurst J; de Vries JW; Ullah S; Frößl K; Gruszka A; Löscher M; Bartz-Schmidt KU; Spitzer MS; Herrmann A
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9445-9456. PubMed ID: 33528240
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine-montmorillonite hybrid formulation for topical drug delivery to the eye.
Park CG; Choi G; Kim MH; Kim SN; Lee H; Lee NK; Choy YB; Choy JH
J Mater Chem B; 2020 Sep; 8(35):7914-7920. PubMed ID: 32726382
[TBL] [Abstract][Full Text] [Related]
18. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid carriers for intraocular brimonidine localisation: development, in-vitro and in-vivo evaluation.
El-Salamouni NS; Farid RM; El-Kamel AH; El-Gamal SS
J Microencapsul; 2018 Jan; 35(1):102-113. PubMed ID: 29310481
[TBL] [Abstract][Full Text] [Related]
20. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
